This article was originally published in Pharmaceutical Approvals Monthly
Company receives "not approvable" letter in May for the antidepressant reboxetine mesylate. FDA has agreed to convene an advisory committee meeting later this year to review the NDA, Pharmacia said. The application was submitted April 29, 1998, and deemed "approvable" in July 1999 and February 2000
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.